Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $180.00 short call and a strike $185.00 long call offers a potential 26.26% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $180.00 by expiration. The full premium credit of $1.04 would be kept by the premium seller. The risk of $3.96 would be incurred if the stock rose above the $185.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 33.57 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
10 Biggest Cancer-Fighting Stocks
Sat, 27 Jul 2019 16:20:00 +0000
The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.
Amgen Controls 98% Of The Shares In Nuevolution After The End Of The Extended Acceptance Period
Fri, 26 Jul 2019 20:00:00 +0000
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. Shareholders in the United States should refer to the section entitled “Important Information to U.S. Shareholders” at the end of this press release. On 22 May 2019 at 08:00 CEST, Amgen Inc. (“Amgen”) (AMGN) announced a recommended public cash offer to the shareholders of Nuevolution AB (publ) (“Nuevolution”) to tender all their shares in Nuevolution to Amgen (the “Offer”) for SEK 32.50 per share in cash.
What's in the Cards for Pfizer (PFE) This Earnings Season?
Fri, 26 Jul 2019 16:06:04 +0000
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View
Fri, 26 Jul 2019 15:57:03 +0000
AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.
Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?
Fri, 26 Jul 2019 15:23:03 +0000
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.
Also on Market Tamer…
Follow Us on Facebook